New missile-like radioactive therapy treats prostate cancer
The Institute of Cancer Research (ICR) - 03-Jun-2021Precisely targeted therapy shrank tumours and extends life by 38% in men
Johann de Bono
Consultant at the Institute of Cancer Research
Professor Johann de Bono is Head of the Division of Clinical Studies and an international expert in the development of molecularly targeted cancer therapies against adult cancers. He runs one of the world’s largest phase I clinical trials units for cancer and has also led phase III trials of the prostate cancer drugs abiraterone and cabazitaxel.
Visit website: https://www.icr.ac.uk/our-research/researchers-and-teams/professor-johann-de-bono
See also: 
The Institute of Cancer Research (ICR)
- One of the world’s most influential cancer research organizations
Details last updated 25-Oct-2019
Johann de Bono News
An effective immunotherapy for advanced prostate cancer
BBC - 28-Nov-2019Only 5% saw their tumours shrink, but may be more successful if used earlier
New drug slowed tumour growth in men with prostate cancer
BBC - 30-Sep-2019Olaparib delays cancer growth by months, which means the increased lifespan
Drug attacks cancers cells using trojan horse antibody
Independent - 08-Feb-2019Novel mechanisms for attacking cancer cells are always good news
Prostate cancer treatment with a genetic test
The Institute of Cancer Research (ICR) - 10-Oct-2017Genetic test is a faster, less expensive treatment method for men with advanced prostate cancer
Nine out of ten male prostate cancer sufferers could be treated
Independent - 21-May-2015Study finds prostate cancer is not one disease but several – enabling personalised treatments usi...
